StockData
Protagonist Therapeutics, Inc logo

Protagonist Therapeutics, Inc (PTGX) stock

PTGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 12/30195% above fair value
$121.40−2.62 (-2.11%)

Close on Nov 20, 2026Market cap $7.86BP/E 117.9Yield –

Protagonist Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Protagonist Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was $130.58M, up 252.0% year over year. For fiscal 2025 it was $56.08M, down 69.3% from the year before. The highest annual figure on record is $182.80M in fiscal 2024.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$56.08M-69.3%
FY2024Dec 31, 2024$182.80M–
FY2023Dec 31, 2023-$70.85M–
FY2022Dec 31, 2022-$108.93M–
FY2021Dec 31, 2021-$108.97M–
FY2020Dec 31, 2020-$72.96M–
FY2019Dec 31, 2019-$42.49M–
FY2018Dec 31, 2018-$50.43M-1673.1%
FY2017Dec 31, 2017$3.21M–
FY2016Dec 31, 2016-$30.32M–
FY2015Dec 31, 2015-$14.78M–
FY2014Dec 31, 2014-$8.04M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$218.88M–
Q1 FY2026Mar 31, 2026-$49.16M-139.4%
Q4 FY2025Dec 31, 2025-$37.12M–
Q3 FY2025Sep 30, 2025-$2.03M–
Q2 FY2025Jun 30, 2025-$29.59M-111.0%
Q1 FY2025Mar 31, 2025$124.82M–
Q4 FY2024Dec 31, 2024-$29.49M-274.1%
Q3 FY2024Sep 30, 2024-$28.64M–
Q2 FY2024Jun 30, 2024$268.59M–
Q1 FY2024Mar 31, 2024-$27.67M–
Q4 FY2023Dec 31, 2023$16.94M–
Q3 FY2023Sep 30, 2023-$27.02M–
Q2 FY2023Jun 30, 2023-$26.41M–
Q1 FY2023Mar 31, 2023-$34.36M–
Q4 FY2022Dec 31, 2022-$31.71M–
Q3 FY2022Sep 30, 2022-$25.36M–
Q2 FY2022Jun 30, 2022-$13.93M–
Q1 FY2022Mar 31, 2022-$37.94M–
Q4 FY2021Dec 31, 2021-$27.14M–
Q3 FY2021Sep 30, 2021-$28.74M–
Q2 FY2021Jun 30, 2021-$24.20M–
Q1 FY2021Mar 31, 2021-$28.90M–
Q4 FY2020Dec 31, 2020-$18.99M–
Q3 FY2020Sep 30, 2020-$16.36M–
Q2 FY2020Jun 30, 2020-$21.62M-878.1%
Q1 FY2020Mar 31, 2020-$15.99M–
Q4 FY2019Dec 31, 2019-$14.51M–
Q3 FY2019Sep 30, 2019-$13.94M–
Q2 FY2019Jun 30, 2019$2.78M–
Q1 FY2019Mar 31, 2019-$16.83M–
Q4 FY2018Dec 31, 2018-$10.20M–
Q3 FY2018Sep 30, 2018-$9.42M-123.3%
Q2 FY2018Jun 30, 2018-$15.47M–
Q1 FY2018Mar 31, 2018-$15.35M–
Q4 FY2017Dec 31, 2017-$14.21M–
Q3 FY2017Sep 30, 2017$40.51M–
Q2 FY2017Jun 30, 2017-$12.70M–
Q1 FY2017Mar 31, 2017-$10.40M–
Q4 FY2016Dec 31, 2016-$9.73M–
Q3 FY2016Sep 30, 2016-$7.00M–

More Protagonist Therapeutics figures

See a number that looks wrong?